Patients should not consider allulose a substitute for prescribed GLP-1 agonist medications or expect comparable therapeutic effects for diabetes management or weight loss
Unlike T2D, there is currently very limited coverage of GLP-1s for obesity within the US and EU5
A knowledgeable provider will be honest about the limitations of the evidence rather than repeating marketing claims
BPC 157 Therapy, Interaction with Essential Systems, i.e., Nitric Oxide (NO), Prostaglandins-System, Implicated in the Cytoprotection Concept and Glaucoma For BPC 157 therapy, a common successful result might be the combined evidence, involving essential systems, i.e., nitric oxide (NO)-, prostaglandins-system, long-ago implicated in the cytoprotection concept [1,2,3,4,5,6,7,8,9,10]
J Nutr 115:399410 Zapara TA, Simonova OG, Zharkikh AA et al (2004) Seasonal differences and protection by creatine or arginine pretreatment in ischemia of mammalian and molluscan neurons in vitro
Tempesta E, Troncon R, Janiri L, et al